COPENHAGEN, Denmark, May 10, 2022 (GLOBE NEWSWIRE) – Evaxion Biotech A / S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-based immunotherapies to improve the lives of cancer patients and infectious diseases, announced today that it has successfully produced all batches of personalized cancer immunotherapies for all patients enrolled in the Phase 1 / 2a clinical trial of EVX-02 in adjuvant melanoma.
Birgitte Rønø, Scientific Director of Evaxion, stated: “I am extremely proud that the team behind EVX-02 has proven that this complex production chain is feasible and that we are able to deliver truly unique and personalized DNA vaccines within a critical time frame. And we are delighted to have mastered all stages of the manufacturing process. Each cancer is unique, and so is each immune system, which is why we create cancer therapies that are one-size-fits-all – and only one. “
He continues: “With the release of the final batch, we have confirmed our manufacturing process, which we believe will allow us to advance our DNA cancer immunotherapy programs into larger global studies to further explore the clinical benefits of the compounds. We have once again demonstrated our capabilities to deliver timely personalized cancer treatment tailored to each patient’s unique cancer profile in a clinical trial. “
The custom drug manufacturing process consists of several stages. Sequencing of tumor DNA is followed by artificial intelligence-based identification of the most promising therapeutic targets developed by Evaxion’s proprietary PIONEER ™ technology. This leads to the design of the customized multi-target vaccine pharmaceutical product, which is then manufactured, released at clinical sites and administered to the patient.
This is the second time that Evaxion has conducted a clinical trial with personalized cancer immunotherapy, having previously used a peptide-based treatment.
Our EVX-02 program (NCT04455503) treats adjuvant melanoma patients with our patented DNA-based immunotherapy in combination with standard of care. Patients are completely excised prior to the study, which means their tumors have been successfully removed (surgically). In the study, the goal of therapy is to prevent relapse of the disease. The EVX-02 program is a multicenter study conducted in Australia. There are currently 16 patients enrolled in the study.
Speaking of escapism
Evaxion Biotech A / S is a clinical stage AI-immunology ™ platform company that decodes the human immune system to discover and develop novel immunotherapies for the treatment of cancer, bacterial diseases and viral infections. Building on its proprietary and scalable AI immunology core technology, Evaxion is developing a broad pipeline of new candidate products, including three patient-specific cancer immunotherapies.
For more information
LifeSci Advisors LLC
Corey Davis, PhD
+1 (212) 915 2577
Source: Evaxion Biotech
This announcement contains forward-looking statements that involve material risks and uncertainties. All statements, other than statements of historical facts, included in this announcement regarding the Company’s future operations, plans and objectives are forward-looking statements. Although the Company believes that its expectations are based on reasonable assumptions, all statements other than statements of historical facts included in this announcement about future events are subject to (i) changes without notice and (ii) factors beyond the control of the Company. Company. These statements may include, without limitation, any statements preceded by, followed by, or that include words such as “target”, “believe”, “expect”, “hope”, “aim”, “intend”, “may”, ” could “,” anticipate “,” contemplate “,” continue “,” estimate “,” plan “,” potential “,” foresee “,” plan “,” will “,” may have “,” probably “,” should , “” I would, “” could “and other words and terms with similar or negative meanings. Actual results may differ materially from those indicated by these forward-looking statements due to various factors, including but not limited to: risks associated with your financial condition of the Company and the need for additional capital; risks associated with the Company’s development activity; cost and success of the Company’s product development activities and preclinical and clinical trials; risks related to the commercialization of any approved pharmaceutical product developed or using the Company’s AI platform technology, including the rate and degree of market acceptance of the Company’s candidate products; risks relating to the Company’s dependence on third parties, including for carrying out clinical tests and manufacturing the product; risks associated with the Company’s inability to enter into a partnership; risks related to government regulation; risks associated with the protection of the Company’s intellectual property rights; risks related to employee problems and growth management; risks relating to ADS and the Company’s common stock, risks associated with the pandemic caused by the coronavirus known as COVID-19 and other risks and uncertainties affecting the Company’s business operations and financial condition.
Forward-looking statements are subject to inherent risks and uncertainties beyond the control of the Company which could cause the Company’s actual results, performance or results to differ materially from the expected results, performance or results expressed or implied by such statements. forecast. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as the risks relating to the Company’s business generally, see the risks described in the “Risk Factors” section. included in the Company’s prospectus filed February 5, 2021 and the Company’s current and future reports filed or filed with the US Securities and Exchange Commission (SEC). Any forward-looking statements contained in this announcement are effective only as of the date of this document and, except as required by law, the Company undertakes no obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those set forth in the forward-looking statements, even if new information becomes available in the future.